BLAINJECTIONINJECTABLE
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
SIMPONI ARIA (golimumab) by Johnson & Johnson is tumor necrosis factor receptor blocking activity [moa]. Approved for tumor necrosis factor blocker [epc]. First approved in 2013.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SIMPONI ARIA (golimumab) is a fully human monoclonal antibody that blocks tumor necrosis factor (TNF), a key inflammatory cytokine. It is administered as an intravenous injection and is indicated for autoimmune and inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. The drug reduces inflammation by neutralizing TNF receptor activity, thereby suppressing the immune response underlying these diseases.
$0.039BPart D
PeakProduct is at peak market penetration with $39M in Part D spending; commercial team is likely stable and focused on market maintenance and physician engagement.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
Started May 2024
8 enrolled
Metastatic Castration-Resistant Prostate CarcinomaProstate AdenocarcinomaStage IV Prostate Cancer AJCC v8
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Started Jul 2023
63 enrolled
Psoriatic Arthritis
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Started Sep 2022
577 enrolled
Colitis, Ulcerative
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Started Jul 2022
703 enrolled
Crohn's Disease
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
Started Oct 2021
91 enrolled
Arthritis, Psoriatic
Worked on SIMPONI ARIA at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.